ARANOTE: Adding darolutamide to ADT significantly reduced the risk of radiological progression in patients with mHSPC

ASCO 2024

Genitourinary Cancer

ARASENS: Adding darolutamide to ADT plus docetaxel delays progression to castrate-resistant disease and improves OS in patients with mHSPC

APCCC 2024

Genitourinary Cancer

STAMPEDE: Treatment intensification with ARPI significantly reduces the risk of fracture in patients with mHSPC

ASCO 2024

Genitourinary Cancer

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

ASH 2024

Multiple Myeloma (MM)

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Genitourinary Cancer

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

J Clin Oncol

Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira de Santana Gomes AJ, Cesar de Andrade Mota A, Salman P, Jievaltas M, Ulys A, Jakubovskis M, Kopyltsov E, Han W, Nevalaita L, Testa I, Le Berre MA, Kuss I, Haresh KP

doi: 10.1200/JCO-24-01798

ESMO 2024

Genitourinary Cancer

LBA1. PEACE-3: Adding 223Ra to enzalutamide significantly improves rPFS and OS in patients with mCRPC

APCCC 2024

Genitourinary Cancer

Ideal sequence after ADT alone or ADT plus ARPI for mHSPC

Lung, Respiratory and Thoracic Cancer

Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure?

Lung Cancer

Heijboer FWJ, Mulders TA, van Straten M, Moonen L, Speel EM, von der Thüsen JH, Derks JL, Dingemans AC

doi: 10.1016/j.lungcan.2024.108030

ASH 2024

Leukemia

Related content

ARASENS: Adding darolutamide to ADT plus docetaxel delays progression to castrate-resistant disease and improves OS in patients with mHSPC

STAMPEDE: Treatment intensification with ARPI significantly reduces the risk of fracture in patients with mHSPC

OASIS: Rapid and deep responses to apalutamide plus ADT significantly improved survival in patients with mHSPC treated in real-world practice

EMN15/HOVON147: Adding carfilzomib to Rd significantly improves MRD negativity rates in patients with high-risk smoldering multiple myeloma

Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial

LBA1. PEACE-3: Adding 223Ra to enzalutamide significantly improves rPFS and OS in patients with mCRPC

Ideal sequence after ADT alone or ADT plus ARPI for mHSPC

Radiological follow-up in patients with resected pulmonary carcinoids: Should we reduce radiation exposure?

Quizartinib significantly reduces relapse rates versus midostaurin in newly diagnosed patients with FLT3-ITD-positive AML, based on MAIC analysis